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Background: The frequent occurrence of medicine stockouts represents a significant obstacle to tuberculosis
control in South Africa. Stockouts can lead to treatment alterations or interruptions, which can impact treatment
outcomes. This study investigates the determinants and effects of TB drug stockouts and whether poorer districts
are disproportionately affected.
Methods: TB stockout data, health system indicators and TB treatment outcomes at the district level were extracted
from the District Health Barometer for the years 2011, 2012 and 2013. Poverty terciles were constructed using the
Census 2011 data to investigate whether stockouts and poor treatment outcomes were more prevalent in more
impoverished districts. Fixed-effects regressions were used to estimate the effects of TB stockouts on TB treatment
outcomes.
Results: TB stockouts occurred in all provinces but varied across provinces and years. Regression analysis showed a
significant association between district per capita income and stockouts: a 10% rise in income was associated with
an 8.50% decline in stockout proportions. In terms of consequences, after controlling for unobserved time invariant
heterogeneity between districts, a 10% rise in TB drug stockouts was found to lower the cure rate by 2.10%
(p < 0.01) and the success rate by 1.42% (p < 0.01). These effects were found to be larger in poorer districts.
Conclusions: The unequal spread of TB drug stockouts adds to the socioeconomic inequality in TB outcomes.
Not only are stockouts more prevalent in poorer parts of South Africa, they also have a more severe impact on TB
treatment outcomes in poorer districts. This suggests that efforts to cut back TB drug stockouts would not only
improve TB treatment outcomes on average, they are also likely to improve equity because a disproportionate
share of this burden is currently borne by the poorer districts.
Keywords: Drug stockouts, Tuberculosis, Treatment outcomes, EquityBackground
Medicine shortages affect countries worldwide, but in
particular developing countries [1–4] The evidence to
date is limited but suggests that stockouts are associated
with treatment alteration and discontinuation, and with
worse health outcomes, but none of these studies pro-
vides any estimates of the impact of stockouts on health
outcomes. It also does not examine whether stockouts
affect rich and poor communities differentially.* Correspondence: vandoorslaer@ese.eur.nl
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South Africa for TB medicines for four reasons. First,
South Africa is facing a huge TB epidemic, with 438,000
cases a year and an annual mortality of 123,000 people
[5]. Secondly, South Africa has very high levels of drug
stockouts with 14% of the primary health care facilities
reporting a TB drug stockout in 2011 [6]. Thirdly, TB is
a lethal, but treatable disease and drugs are dispensed
for free to TB patients by the public health clinics, but
periods of stockouts during the six-month treatment
period could have a severe adverse impact on treatment
success. Finally, the country has notoriously high levels
of income inequality [7] which makes it likely that the
drug stockouts do not affect richer and poorer districts
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South Africa’s pharmaceutical chain consists of several
links. The National Department of Health is responsible
for contracting with pharmaceutical companies. Every
two years, the government releases and awards tenders
for TB drugs. The Provincial Departments of Health take
care of the planning, funding, monitoring and evaluation
of pharmaceutical services in the provinces. The Provin-
cial Medicine Depots are responsible for procurement
and storage of the drugs, and for their delivery to district
pharmacies and health facilities. Health facilities can
order medicines at the Provincial Medicine Depot or at
district pharmacies [8].
A performance audit of the management of pharma-
ceuticals in South Africa revealed that problems occur at
many points along the pharmaceutical chain [8]. Poten-
tial reasons for stockouts at the National and Provincial
Departments of Health are late drug tenders; essential
medicines not provided in government tenders; lack of
policies to manage pharmaceuticals; inadequate budgets
for the population’s health needs; and, lack of oversight
[8]. Causes of drug stockouts at the pharmaceutical
companies are sudden unforecasted increases in demand
(e.g. because of guideline changes without sufficient
preparation); shortages of active ingredients; manufac-
turing issues; and, the limited number of pharmaceutical
companies due to mergers and acquisitions [4, 8–10].
The relatively small number of pharmaceutical compan-
ies makes the pharmaceutical chain vulnerable to unex-
pected events [11]. In case of a shortage at the supplier,
the supplier will first deliver to provinces that impose
penalties for late delivery. Only two of the nine prov-
inces impose such penalties (Gauteng and the Western
Cape) [8].
Causes of drug stockouts in the medicine depots and
health facilities include damage, expiry and theft due to
poor storage and stock management. Other causes are a
lack of resources - which can result in late or
non-payment of pharmaceutical companies; lack of
skilled staff; unexpected demand due to unpredictable
migration patterns; poor infrastructure, theft and cor-
ruption [12]; and, inadequate stock monitoring [2, 4, 8].
Appropriate drug stock management at the Provincial
Department of Health, Provincial Medicine Depots and
health facilities requires a comprehensive monitoring
system, skilled staff and good infrastructure. There are
several reasons why stockouts may affect poor districts
more. First, poorer districts often struggle to attract
skilled and experienced staff and have worse infrastruc-
ture [13]. Secondly, remote areas are more likely to be
poorer, which generates additional demands on re-
sources and logistics to deliver drugs to these locations.
Finally, the two most affluent provinces in South Africa
(Western Cape and Gauteng) often get preferentialtreatment from suppliers because they impose penalties
for late delivery.
Regarding the consequences of drug stockouts, several
other studies in sub-Saharan Africa have suggested that
medicine shortages may affect treatment and treatment
outcomes [6, 14, 15]. A study in Malawi showed that
one of the reasons for changing the HIV treatment regi-
men was drug stockouts [14]. A study in Ivory Coast
found that stockouts caused 9% of the HIV treatment
discontinuations and 30% of the treatment alterations.
Patients who interrupted treatment because of stockouts
had an increased probability of dying in comparison to
patients who continued treatment [15]. Seunanden and
Day [6] found that TB drug stockout rates in South
Africa were associated with higher death rates in 2011.
These findings for developing countries are in line
with findings from studies on drug stockouts conducted
in developed countries [10, 16–18]. In the United States
shortage of the injectable anaesthetic drug propofol
caused infection risk for 40,000 patients due to mistakes
with a different dosage of the drug [16]. Moreover, lower
event-free survival rates were seen in children with can-
cer treated on a different regimen due to drug stockouts
[17]. Drug stockouts may also have an impact on costs
because they increase the workload for health staff, as
alternative treatments have to be found. Alternative
drugs can also be more costly [18]. This has economic
consequences: A survey conducted in the United States
showed that approximately US $216 million was spent
to manage drug stockouts on an annual basis [10].
Drug stockouts can also impede treatment adherence
[19, 20]. Strict treatment adherence is crucial for suc-
cessful TB treatment [21–23] (Additional file 1: Box 1).
This knowledge and existing literature on drug stock-
outs, lead us to expect that TB drug stockouts have a
negative impact on TB treatment outcomes. This nega-
tive impact has not yet been demonstrated in other
work, like [6] who reported a positive correlation be-
tween TB drug stockouts and TB deaths, but without
further control for confounding due to observed and un-
observed factors. In our study we adopted a fixed-effects
regression approach to better control for possible con-
founding factors and examined the heterogeneity of
health effects by district poverty. We also focused on the
public primary care sector, since this is where most cases
of TB are treated in South Africa [21].
Methods
We use two data sources that were linked at the district
level. The District Health Barometer [24] was used to
extract TB drug stockout data, TB health outcomes and
health system characteristics. This dataset contains
annually aggregated indicators of public primary health
facilities in South Africa for the years 2011, 2012 and
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was obtained from the Census survey 2011 [25] house-
hold data and then aggregated at the district level.
Variable definitions and descriptive statistics can be
found in Tables 1 and 2. Of the 52 districts in South Af-
rica 51 were included, as stockout proportions were
missing for Tshwane District. Stockout proportions were
also missing for Eden and Overberg in 2012 and for
Central Karoo and Cape Town in 2011 (all located in
the Western Cape Province).
Statistical analysis
First, we describe differences in average TB drug stock-
outs and TB treatment outcomes by district between
poverty categories.1 Districts were divided into three
poverty categories: districts with lowest poverty (poverty
rate 26–35%), districts with intermediate poverty
(poverty rate 35–42%), and districts with highest poverty
(poverty rate 42–52%). Average values of stockouts and
treatment outcomes were compared with a one-way
ANOVA.
To investigate potential determinants of TB drug
stockout proportions per district, we ran a weighted re-
gression analysis on a number of covariates. Mean per
capita household income and degree of urbanisation of a
district were used as proxies for district socioeconomic
status. Provincial and local government spending per
health visit was included as a health system characteris-
tic. A dummy variable was included for the district with
the provincial medicine depot location. Due to the
skewed distribution of district income, log transform-
ation was applied to the income variable. Time effects
and province effects are captured by a year and province
dummy, and observations were weighted based on theTable 1 Definition of the indicators
Indicator Definition
TB stockout proportion Annual proportion of primary h
report a stockout when any of
reported. The numerator of this
the number of reporting faciliti
TB cure rate Percentage of new smear-positi
treatment, and at least one tim
TB success rate Percentage of all TB patients on
who were cured (smear negativ
TB death rate Percentage of all TB patients on
TB incidence Number of TB patients on treatm
TB/HIV coinfection Percentage of TB patients on tre
Expenditure/visit Provincial and local governmen
the non-privately insured popu
District income Average income in South Africa
Urban Proportion of people in a distric
TB indicators and expenditure/visit extracted from District Health Barometer [24]. Dnumber of TB patients on treatment to give greater
weight to districts with larger volumes of TB patients on
treatment.
To examine the effect of TB stockouts on three treat-
ment outcomes by district, i.e. TB cure rate, TB success
rate and TB death rate, we used a regression with time
and district fixed effects. This method not only exploits
the time variation between years but also within districts
to identify effects on TB outcomes. No lagged effects
were included because all treatment outcomes are
short-term effects; the duration of standard TB treat-
ment is six months [21] and most TB deaths occur in
the first months of treatment [26]. As the fixed-effect
regression has the advantage that it controls for all
time invariant unobservable district factors, most of
the potential omitted variable bias is avoided. This is
important, because there might be specific unobserv-
able district characteristics that affect both the drug
stockout proportion and the treatment outcomes.2
Moreover, we also control for two time varying fac-
tors: TB incidence and TB/HIV co-infection which
have been shown to affect TB treatment outcomes
negatively [27, 28]. Due to the high HIV-TB coinfec-
tion rates and the increase in ART coverage over this
period, we also include an estimate of ART coverage
in the regressions. The ART coverage rate for each
district was estimated as the number of patients on
ART as share of the population.
Under the assumption that were no other unobserved
factors that varied over time together with the stockouts,
we interpret the estimated coefficient of the stockout
variable as a causal effect. The analysis was performed
for the whole sample and separately for each poverty
category. Statistical significance testing of differences inealth care facilities reporting at least one TB drug stockout. Facilities
the TB drugs are out of stock. Length of stockout duration is not
proportion is all facilities that reported a stockout. The denominator is
es.
ve TB patients who were smear negative in the last month of their
e before.
treatment (smear positive, smear negative, extra-pulmonary patients)
e) or completed treatment (not cured, but finished treatment).
treatment who died
ent per 100,000 inhabitants
atment who are infected with HIV
t expenditure in South African Rand on primary health care per visit for
lation
n Rand per capita in a district
t who live in a city
istrict income and urban extracted from Census 2011 [25]
Table 2 Descriptive statistics
Indicator Mean SD Min Max
TB stockout proportion 10.49 8.76 0.10 44.30
TB cure rate 74.58 8.14 47.92 95.68
TB success rate 74.66 7.03 46.74 90.12
TB death rate 9.18 3.27 2.78 16.93
TB incidence 774.21 262.07 285.04 1511.92
TB/HIV coinfection 86.79 7.73 49.53 98.45
Expenditure/visit 301.51 51.74 175.32 469.13
District income 50,032 22,530 19,535 121,421
Urban 0.59 0.32 0.05 1.00
SD = standard deviation, Min =minimum value, Max =maximum value
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interactions between the stockout proportion and the
poverty category.
We also performed robustness check by adding pa-
tients who were classified as lost to follow to the dis-
trict's TB deaths. This was done because the TB death
rate might be an underestimation of the TB deaths be-
cause it misses TB cases that were lost to follow-up prior
to their deaths3 (Additional file 1: Table S9).Results
There is substantial variation in TB stockout proportions
across provinces and across the years 2011, 2012 and
2013 (Fig. 1). In our study period, the Western Cape was
on average the province with the lowest and the
Northern Cape the province with the highest stockout
proportions (3.84 vs. 16.52).Fig. 1 Average district TB stockout proportions, by province in 2011, 2012Table 3 lists the average TB stockout proportions by
district and TB treatment outcomes by district by
poverty categories. TB stockout proportions are higher
and TB treatment outcomes are seen to be worse in dis-
tricts with higher poverty. The ANOVA confirms that
TB outcomes vary by level of poverty of the district.
What determines stockout proportions?
The regression analysis for 2011–2013 shows that dis-
trict per capita income is negatively associated with
stockouts (Table 4). Ceteris paribus, a 10% rise in in-
come (log transformed income) is associated with an
8.5% decline in TB stockout proportions. Having the
Provincial Medicine Depot located in the district is asso-
ciated with higher stockout proportions (p-value < 0.05).
Provincial and local government expenditure per visit
and degree of urbanisation are not correlated with TB
stockouts.
Effects of stockouts on TB treatment outcomes
Figures 2, 3 and 4 show graphical plots of the association
between TB treatment outcomes and TB drug stockouts
at the district level. While there appears to be a negative
correlation between TB cure rates, TB success rates and
TB drug stockouts (Figs. 2 and 3), a positive correlation
is observed between TB death rates and TB drug stock-
outs (Fig. 4). This suggests that, in general, districts with
more TB drug stockouts are likely to experience worse
TB treatment outcomes.
The regression analysis for all districts demonstrates
that TB drug stockouts have a significant negative effect
on TB cure rates and TB success rates (Tables 5 and 6).
It suggests that, in the period considered, a 10% rise inand 2011. Rates are weighted by number of patients on TB treatment
Table 3 Mean TB stockout proportions and TB treatment outcomes by district poverty category
Poverty category TB drug stockouts TB cure rate TB success rate TB death rate
Least poor 9.496 76.04 76.66 7.894
(1.280) (0.816) (0.735) (0.506)
Middle 9.229 75.05 74.36 9.054
(1.081) (1.301) (1.207) (0.457)
Poorest 12.67 72.20 72.65 10.66
(1.324) (1.198) (0.902) (0.323)
P value ANOVA
Least poor vs. middle 0.82 0.50 < 0.01 < 0.05
Least poor vs. poorest < 0.01 < 0.01 < 0.01 < 0.01
Middle vs. poorest < 0.05 < 0.01 0.16 < 0.01
Percentage of people living in poverty in the least poor districts: 26–35%, middle: 35–42%, poorest: 42–52%. Tested with one-way ANOVA. Standard error
in parentheses
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cline of the TB cure rate and a 1.43% decline of the TB
treatment success rate. Tables 5, 6 and 7 show that the
negative consequences of TB drug stockouts were largest
in the poorest districts. In those, a 10% increase in TB
drug stockout proportion led to a 3.25% decline in the
TB cure rate and a 2.78% decline in the TB success rate.
In the districts with the lowest poverty rates, we did not
find any significant effect of TB drug stockouts on TB
treatment outcomes.
The results for death rates are more surprising.
Overall, we do not find any effect on death rates. But for
the districts in the middle category we found that anTable 4 Weighted least squares (WLS) regression results
determinants of TB drug stockouts
Variables WLS ‘11-‘13
TB drug stockouts
Log income −8.499**
(3.273)
Expenditure/visit −0.00881
(0.0137)
Urban 2.266
(3.836)
Provincial Medicine Depot 3.210**
(1.356)
Constant 106.9***
(32.48)
Observations 149
R-squared 0.599
Standard errors in parentheses
***p < 0.01, **p < 0.05, *p < 0.1
Time and province effects are captured by year and province dummies.
Districts were weighted based on the number of TB patients on treatment to
give greater weight to districts with larger volumes of TB patients
on treatmentincrease of 10% in districts stockouts results in an in-
crease of 0,46% of deaths. For the poorest districts, the
result is more surprising. The coefficient is negative and
significantly different from zero at the 5% level of signifi-
cance. However, we are concerned that this counterintu-
itive result may be attributable to the underestimation of
the TB death rate because it misses TB cases that were
lost to follow-up prior to their deaths3. We do not find
any significant effect of TB drug stockouts on this com-
bined outcome measure of TB deaths and patients lost
to follow up.
Discussion
Our study is the first that has tried to exploit the
variation in drug stockouts across districts and over time
in South Africa to examine the determinants and the
effects of TB drug stockouts.
First, we found that TB drug stockouts are more
prevalent in districts with lower income: a 10% rise in
income was associated with an 8.5% decline in TB drug
stockouts. This suggests that poorer districts are likely
to suffer a greater burden of stockouts.
Secondly, and contrary to a priori expectation, we
found that districts in which the Provincial Medicine
Depot was located were more likely to experience a TB
drug stockout. This suggests that greater distance to a
Provincial Medicine Depot does not appear to operate as
a constraint on adequate stock levels in South Africa. It
also suggests that facilities located in the same district as
the provincial depot overly reliant on the provincial
depot.
Third, after controlling for time invariant unobserv-
ables, we estimate that TB stockouts had substantial
negative effects on TB cure and success rates by district.
Our results indicate that, on average, a 10% rise in the
TB drug stockout proportion results in a 2.14% decline
in TB cure rate and a 1.43% decline in TB success rate.
Fig. 2 Association between TB cure rate and TB drug stockouts. Fitted line is weighted by number of people on TB treatment (shown by dot size)
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larger in the districts with higher poverty rates. This
confirms that the negative effects are primarily concen-
trated in the poorest districts of South Africa and are
likely to further exacerbate the socioeconomic inequal-
ities in TB treatment outcomes.
Our results imply that TB drug stockouts can limit the
effective control of the TB epidemic, especially in
districts with higher rates of poverty. This is because,
when fewer patients are cured, more patients remain in-
fectious and are able to spread TB. Improved reliabilityFig. 3 Association between TB success rates and TB drug stockouts. Fitted linof the TB drug supply is therefore essential to enhance
the effectiveness of TB epidemic control.
The finding that TB drug stockouts seem to have a
greater negative impact on TB cure rates than on TB
success rates deserves further discussion. The TB cure
rate measures the fraction of all smear-positive TB
patients who are smear negative in the last two months
of their treatment. The TB success rate measures the
fraction of all TB patients who completed their treat-
ment and all smear-positive TB patients who are smear
negative in the last two months of their treatment.e is weighted by number of people on TB treatment (shown by dot size)
Fig. 4 Association between TB death rates and TB drug stockouts. Fitted line is weighted by number of people on TB treatment (shown by dot size)
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to Genexpert4 in 2012 which means that a small
minority of patients receive smear tests. For patients
who did not receive smear tests the success rate
merely captures whether they have had a recent clinic
visit to collect their treatment. Patients included in
the TB success rate are therefore not necessarily
cured. For TB to be cured, the treatment regimen
must be followed strictly and interruptions can have
serious consequences for cure [21–23], whilst for TB
success treatment must be completed. Interruptions
may therefore have less impact, as reflected in our
results.Table 5 Regression results for TB cure rate
Variables TB cure rate TB
Poverty category All Le
TB drug stockout proportion −.214*** .04
(.069) (.1
Conf interval −.351/−.076 −.1
Constant 81.237*** 77
(12.731) (26
Conf interval 55.952/106.523 23
District FEs Yes Ye
Year FEs Yes Ye
Observations 149 44
Number of districts 51 16
R-squared 0.049 0.0
Standard errors in parentheses
***p < 0.01, **p < 0.05, *p < 0.1
Note: Analysis was controlled for TB/HIV coinfection, TB incidence and ART coveragThe finding of a negative impact of TB drug stockouts
and TB death rates in the poorest districts is counterin-
tuitive, but the further analysis with lost to follow up
patients suggests that the initial finding may be attribut-
able to missed deaths and the higher concentration of
such missed deaths in poorer districts.
We found that the effects of TB drug stockouts are
worse in districts with more people living in poverty.
This could be due to the fact that in these districts
patients have fewer options to look for alternatives to
access TB drugs. When a health facility has a stockout,
patients can go to another health facility to collect their
TB drugs. This requires extra travel and involves timecure rate TB cure rate TB cure rate
ast poor Middle Poorest
8 −.254** −.325**
15) (.096) (.124)
890/.285 −.452/ -.057 −.578/ -.072
.200*** 64.862*** 125.070***
.083) (17.560) (23.090)
.107/131.293 28.894/100.830 77.914/172.227
s Yes Yes
s Yes Yes
51 54
17 18
95 0.409 0.045
e. Districts were weighted based on the number of TB patients on treatment
Table 6 Regression results for TB success rate
Variables TB success rate TB success rate TB success rate TB success rate
Poverty category All Least poor Middle Poorest
TB drug stockout proportion −.143*** .070 −.160** −.278**
(.054) (.083) (.070) (.103)
Conf interval −.250/.037 −.102/.242 −.303/−.017 −.489/−.067
Constant 82.203*** 91.210*** 68.765*** 101.187***
(9.915) (18.872) (12.722) (19.318)
Conf interval 62.512/101.895 52.072/130.348 42.705/94.825 61.734/140.638
District FEs Yes Yes Yes Yes
Year FEs Yes Yes Yes Yes
Number of districts 51 16 17 18
R-squared 0.003 0.152 0.290 0.047
Standard errors in parentheses
***p < 0.01, **p < 0.05, *p < 0.1
Note: Analysis was controlled for TB/HIV coinfection, TB incidence and ART coverage. Districts were weighted based on the number of TB patients on treatment
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TB medicine at a private pharmacy or clinic. When
these options are not feasible for cash-constrained
patients, they are forced to interrupt TB treatment until
the TB drugs are available.
TB medicines were not the only drugs that have had
stockout problems in South Africa. Stockout surveys
[29–31] have shown that many other essential medicines
were also affected. This problem was acknowledged by
the National Department of Health and some measures
have been taken to curb the problem [32]. However, and
in spite of these, 20% of health facilities in South Africa
still reported stockouts of essential medicines (including
TB drugs) in 2016 [33].
Since the consequences of TB drug stockouts for TB
treatment outcomes are severe, emphasis should be
placed on further strengthening of the pharmaceutical
chain in South Africa. A short-term solution to ensureTable 7 Regression results for TB death rate
Variables TB death rate T
Poverty category All L
TB drug stockout proportion −.009 .0
(.014) (.
Conf interval −.037/.019 −
Constant 12.390*** 4
(2.616) (7
Conf interval 7.195/17.585 −
District FEs Yes Y
Year FEs Yes Y
Number of districts 51 1
R-squared 0.004 0
Standard errors in parentheses
***p < 0.01, **p < 0.05, *p < 0.1
Note: Analysis was controlled for TB/HIV coinfection, TB incidence and ART coveragcontinuous drug supply to TB patients could be a
public-private partnership in which TB patients can
collect their TB drugs for free at a private pharmacy or
-clinic in the case of a stockout in the public health
facility.5
While contributing to the literature on the subject,
our study also has limitations. First, the aggregated an-
nual stockout proportion at the district level is measured
with substantial imprecision. The district stockout pro-
portion was not weighted by clinic size and does not in-
clude any information about the duration of the
stockout. As a result, a stockout of a few days is
weighted equally to a stockout of a month. Since the
publicly available data were already aggregated and not
available at the facility level, it was not possible to adjust
and refine these rates. Secondly, as our analysis was per-
formed at the district level, it may suffer from ecological
fallacy or bias. Some districts are quite large andB death rate TB death rate TB death rate
east poor Middle Poorest
01 .046* −.049**
031) (.027) (.022)
.064/.066 −.009/.101 −.093/−.004
.930 13.642*** 13.804***
.158) (4.880) (4.052)
9.914/19.774 3.647/23.638 5.529/22.078
es Yes Yes
es Yes Yes
6 17 18
.182 0.226 0.053
e. Districts were weighted based on the number of TB patients on treatment
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and TB treatment outcomes between clinics within
districts exist. TB drug stockouts can occur in one clinic,
whereas bad TB treatment outcomes can occur in another
clinic. These differences disappear when TB drug stockout
proportion and TB treatment outcomes are averaged on a
district level. A potential future analysis at facility level
could solve this problem but will run into another prob-
lem: that of attributing TB patients to clinics. Last but not
least, the fixed-effect regression analysis controlled for
time invariant unobservables, TB incidence and HIV coin-
fection. To the extent that any other relevant time varying
unobservables were omitted, our estimates may still be
subject to some omitted variable bias.Conclusion
The persistence of TB drug stockouts in South Africa
not only hampers the effective control of TB but its un-
equal occurrence across districts also adds to the socio-
economic inequality in TB outcomes. We find that
stockouts are not only more prevalent in poorer parts of
South Africa, they also have greater detrimental effects
on the TB treatment outcomes of the poorer districts.
This suggests that efforts to reduce TB drug stockouts
are essential in the fight against the TB burden and its
impact on socioeconomic inequality.Endnotes
1A poverty threshold of R575 (South African Rand)
per month per household was used. This is an inflation
adjusted lower-bound poverty line, estimated with the
cost-for-basic needs poverty line suggested by Özler
[34, 35]). Table 8 in the Appendix lists the districts
by poverty category.
2An example of a potential unobserved district charac-
teristic is ‘bad governance’. This can influence TB drug
stockouts, because stock management might be inad-
equate. And it can influence TB treatment outcomes, be-
cause TB treatment guidelines might not be implemented
in health facilities.
3See Health Systems Trust [36].
4Genexpert is a molecular TB test detecting the pres-
ence of TB bacteria. Its main advantages are that it can
give a result in less than two hours (accurate culture tests
can take weeks); that it is more sensitive than sputum mi-
croscopy for HIV-positive patients; and, that it also tests
for resistance to the drug Rifampicin. It was endorsed by
the WHO in 2010. One of the main downsides is that it
cannot be used to monitor treatment progress given that
it detects both live and dead bacteria.
5For an example of such an experiment, see e.g. the
Central Chronic Medicine Dispensing and Distribution
Programme (CCMDD) available at http://www.hst.org.za/hstconference/hstconference2016/Presentations/roma_
ramphal_hst_conf_final_04.05.2016.pdf.
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An overview of the South African districts divided into poverty categories.
Table S9. Regression results for TB death rate + lost to follow up (DLTFU):
The results of the regression analysis for TB stockouts on TB death rate
including lost to follow up patients. (DOCX 29 kb)
Abbreviations
ART: Antiretroviral therapy; Conf interval: Confidence interval; DLTFU: Death
rate + lost to follow up; FE: Fixed effects; HIV: Human immunodeficiency
virus; Max: Maximum value; Min: Minimum value; SD: Standard deviation;
TB: Tuberculosis; WLS: Weighted least squares
Acknowledgements
We acknowledge Cobus Burger and Candy Day for their helpful input.
Funding
The authors are grateful to the Erasmus Trust Fund for funding of a research
project on Patient incentives to encourage improved TB treatment in South
Africa [WBS nr 22020000.018.002]. The Erasmus Trust Fund did not have a
role in the design of the study, the collection, analysis, interpretation of data,
and in writing the manuscript.
Availability of data and materials
We used two data sources. The District Health Barometer was used to extract
TB drug stockout data, TB health outcomes and health system characteristics.
Socioeconomic information was obtained from the Census survey 2011.
Availability:
– District Health Barometer 15/16: http://www.hst.org.za/publications/
Pages/-District-Health-Barometer-201516.aspx
– Census 2011 on request: http://www.statssa.gov.za/?page_id=3839
Authors’ contributions
LEMK was responsible for the literature review, the analysis and the first draft.
RB and EKAD made important contributions to the statistical analysis, the
discussion and revised the manuscript critically. All authors read and
approved the final version of the manuscript. All authors agreed to be
accountable for all aspects of the work in ensuring that questions related to
the accuracy or integrity of any part of the work are appropriately
investigated and resolved.
Ethics approval and consent to participate
Not applicable. Health District Barometer data is open accessible at the website
of Health Systems Trust, no approval was needed to retrieve this data.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Erasmus School of Health Policy and Management, Erasmus University
Rotterdam, Burgemeester Oudlaan 50, Rotterdam, PA 3062, The Netherlands.
2Department of Economics, Stellenbosch University, Stellenbosch, South
Africa. 3Erasmus School of Economics, Erasmus University Rotterdam,
Burgemeester Oudlaan 50, Rotterdam, PA 3062, The Netherlands.
Koomen et al. BMC Health Services Research          (2019) 19:213 Page 10 of 10Received: 11 June 2018 Accepted: 25 February 2019
References
1. American Hospital Association. AHA survey on drug shortages. 2011.
2. Besançon L, Chaar B. Report of the international summit on medicines
shortage [internet]. 2013. Available from: https://fip.org/files/fip/publications/
FIP_Summit_on_Medicines_Shortage.pdf
3. Masters SH, Burstein R, Decenso B, Moore K, Haakenstad A, Ikilezi G, et al.
Pharmaceutical availability across levels of care: evidence from facility
surveys in Ghana, Kenya, and Uganda. PLoS One. 2014;9(12):1–12.
4. Hedman L. Medicines shortages. WHO Drug Inf Bull. 2016;30(2):180–5.
5. World Health Organization (WHO). South Africa tuberculosis profile [Internet].
2017. Available from: https://extranet.who.int/sree/Reports?op=Replet&name=
%2FWHO_HQ_Reports%2FG2%2FPROD%2FEXT%2FTBCountryProfile&ISO2=
ZA&LAN=EN&outtype=html
6. Seunanden T, Day C. The extent and impact of TB drug stock-out. South
African Heal Rev. 2014:173–89.
7. Leibbrandt M, Finn A, Woolard I. Describing and decomposing post-
apartheid income inequality in South Africa. Dev South Afr. 2012;29(1):19–34.
8. Auditor General South Africa. Performance audit of the management of
pharmaceuticals [Internet]. 2016. Available from: http://www.agsa.co.za/Portals/0/
Downloads/AGSA%20Performance%20Audit%20Management%20
Pharmaceuticals%20-%20Part%201.pdf Performance Audit Management
Pharmaceuticals - Part 1.pdf.
9. Yadav P. Health product supply chains in developing countries: diagnosis of
the root causes of underperformance and an agenda for reform. Heal Syst
Reform [Internet]. 2015;1(2):142–54 Available from: http://www.tandfonline.
com/doi/full/10.4161/23288604.2014.968005.
10. Fox ER, Sweet B V., Jensen V. Drug shortages: A complex health care crisis.
Mayo Clin Proc [Internet]. Elsevier Inc; 2014;89(3):361–373. Available from:
https://doi.org/10.1016/j.mayocp.2013.11.014.
11. Gagnon MA. Drug shortages: searching for a cure. Healthc Policy.
2012;7(4):10–7.
12. Bateman C. Drug stock-outs: inept supply-chain management and
corruption. South African Med J. 2013;103(9):600–2.
13. Reid S. Monitoring the effect of the new rural allowance for health
professionals. Heal Syst Trust [Internet]. 2004:1–7 Available from: https://
www.researchgate.net/publication/322273005_Monitoring_the_effect_of_
the_new_rural_allowance_for_health_professionals.
14. Barnett BS, Chaweza T, Tweya H, Ngambi W, Phiri S, Hosseinipour MC.
Assessment of non-standard HIV antiretroviral therapy regimens at
lighthouse Trust in Lilongwe, Malawi. Malawi Med J. 2016;28(1):6–9.
15. Pasquet A, Messou E, Gabillard D, Minga A, Depoulosky A, Deuffic-Burban S, et al.
Impact of drug stock-outs on death and retention to care among HIV- infected
patients on combination antiretroviral therapy in Abidjan, cote d’ivoire. PLoS One.
2010 Oct 15;5(10):e13414. https://doi.org/10.1371/journal.pone.0013414.
16. Jensen V, Rappaport B. The reality of drug shortages—the case of the
injectable agent propofol. N Engl J Med [Internet]. 2010;28:806–7 Available
from: https://www.researchgate.net/publication/44679864_The_Reality_of_
Drug_Shortages_-_The_Case_of_the_Injectable_Agent_Propofol.
17. Metzger ML, et al. The impact of drug shortages on children with Cancer —
the example of Mechlorethamine. N Engl J Med [Internet]. 2012;363(26):1–3
Available from: http://scholar.google.com/scholar?hl=en&btnG=Search&q=
intitle: New+engla+nd+journal#0.
18. Tan YX, Moles RJ, Chaar BB. Medicine shortages in Australia: causes, impact
and management strategies in the community setting. Int J Clin Pharm
Springer International Publishing; 2016;38(5):1133–1141.
19. Kranzer K, Ford N. Unstructured treatment interruption of antiretroviral
therapy in clinical practice: a systematic review. Trop Med Int Heal.
2011;16(10):1297–313.
20. Shiotani R, Hennink M. Socio-cultural influences on adherence to tuberculosis
treatment in rural India. Glob Public Health [Internet]. Taylor & Francis; 2014;1–
13. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25223868
21. TB DOTS Strategy Coordination. National Tuberculosis Management Guidelines
2014 [Internet]. 2014. 19–28 p. Available from: http://www.tbonline.info/media/
uploads/documents/ntcp_adult_tb-guidelines-27.5.2014.pdf.
22. Gelmanova IY, et al. Barriers to successful tuberculosis treatment in Tomsk,
Russian Federation: non-adherence, default and the acquisition of multidrug
resistance. Bull World Heal Organ [Internet]. 2007;85(10):703–11. Available
from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2636414/.23. Wells et al. HIV infection and multidrug-resistant tuberculosis—the perfect
storm. J Infect Dis [Internet]. 2007;196(s1):S86–107 Available from: https://
academic.oup.com/jid/article-lookup/doi/10.1086/518665.
24. Massyn N, Peer N, Padarath A, Barron P, Day C, Trust HS, et al. District health
barometer 2015/16. Heal Syst Trust [Internet]. 2016;626. Available from: http://
www.hst.org.za/publications/Pages/-District-Health-Barometer-201516.aspx
25. South African Census 2011. Pretoria: Statistics South Africa, 2011. http://
www.statssa.gov.za
26. Harries AD, Hargreaves NJ, Gausi F, Kwanjana JH, Salaniponi FM. High early
death rate in tuberculosis patients in Malawi. Int J Tuberc Lung Dis.
2001;5(11):1000–5.
27. Davies PD. Drug-resistant tuberculosis. J R Soc Med. 2001;94(6):261–3.
28. Kennedy SB, Campbell J, Hester RA. HIV-associated tuberculosis among a
cohort of heterosexual discordant couples in Lusaka, Zambia.
J Health Popul Nutr. 2002;20(4):289–96.
29. Stop Stockouts. Stock outs in South Africa – a National Crisis, vol. 36; 2013.
Available from: https://stockouts.org/Download/stop_stockouts_report_
2013pdf_1.pdf
30. Stop Stockouts. Stock outs in South Africa second. Annu Rep. 2014;
Available from: https://stockouts.org/Download/stockouts_2014_final_
online.pdf.
31. Stop Stockouts. 2015 Stock Outs National Survey - Third Annual Report –
South Africa. p. 2015. Available from: https://stockouts.org/Download/2015_
stock_outs_national_survey.pdf
32. Auditor General South Africa. Corrective actions and initiatives implemented
by management. Performance audit on the management of
pharmaceuticals at departments of Health [Internet]. 2016. Available from:
http://www.agsa.co.za/Portals/0/Downloads/
AGSA%20Performance%20Audit%20Management%20Pharmaceuticals%20-
%20Part%202.pdf.
33. Health systems Trust. District health information system [Internet]. 2016.
Available from: http://www.hst.org.za/publications/Pages/-District-Health-
Barometer-201516.aspx.
34. Özler B. Not separate, not equal: poverty and inequality in post-apartheid
South Africa. Econ Dev Cult Change [Internet]. 2007;55(3):487–529 Available
from: http://www.journals.uchicago.edu/doi/10.1086/511191.
35. Statistics South Africa. CPI history South Africa. Vol. 2016:1.
36. Health systems Trust. Health systems Trust [Internet]. 2016. Available from:
http://www.hst.org.za/aboutus
